Department of Endocrinology and Diabetes, Saitama Medical University, Morohongo 38, Moroyama, Iruma-gun, Saitama, 350-0495, Japan.
Department of Home Care Medicine, Sowa Hospital, Sagamihara, Kanagawa, Japan.
BMC Endocr Disord. 2020 Jan 13;20(1):9. doi: 10.1186/s12902-020-0490-0.
Primary aldosteronism (PA) plus subclinical Cushing's syndrome (SCS), PASCS, has occasionally been reported. We aimed to clinically characterize patients with PASCS who are poorly profiled.
A population-based, retrospective, single-center, observational study was conducted in 71 patients (age, 58.2 ± 11.2 years; 24 males and 47 females) who developed PA (n = 45), SCS (n = 12), or PASCS (n = 14). The main outcome measures were the proportion of patients with diabetes mellitus (DM), serum potassium concentration, and maximum tumor diameter (MTD) on the computed tomography (CT) scans.
The proportion of DM patients was significantly greater in the PASCS group than in the PA group (50.0% vs. 13.9%, p < 0.05), without a significant difference between the PASCS and SCS groups. Serum potassium concentration was significantly lower in the PASCS group than in the SCS group (3.2 ± 0.8 mEq/L vs. 4.0 ± 0.5 mEq/L; p < 0.01), without a significant difference between the PASCS and PA groups. Among the 3 study groups of patients who had a unilateral adrenal tumor, MTD was significantly greater in the PASCS group than in the PA group (2.7 ± 0.1 cm vs. 1.4 ± 0.1 cm; p < 0.001), without a significant difference between the PASCS and SCS groups.
Any reference criteria were not obtained that surely distinguish patients with PASCS from those with PA or SCS. However, clinicians should suspect the presence of concurrent SCS in patients with PA when detecting a relatively large adrenal tumor on the CT scans.
原发性醛固酮增多症(PA)合并亚临床库欣综合征(SCS),即 PASCS,偶有报道。我们旨在对特征不明显的 PASCS 患者进行临床分析。
进行了一项基于人群的回顾性单中心观察性研究,共纳入 71 名患者(年龄 58.2±11.2 岁;男 24 例,女 47 例),这些患者分别患有 PA(n=45)、SCS(n=12)或 PASCS(n=14)。主要观察指标为糖尿病(DM)患者的比例、血清钾浓度和 CT 扫描的最大肿瘤直径(MTD)。
与 PA 组(13.9%)相比,PASCS 组 DM 患者的比例显著更高(50.0%,p<0.05),但与 SCS 组无显著差异。与 SCS 组相比,PASCS 组血清钾浓度显著更低(3.2±0.8 mEq/L 比 4.0±0.5 mEq/L;p<0.01),但与 PA 组无显著差异。在单侧肾上腺肿瘤的 3 组患者中,PASCS 组的 MTD 显著大于 PA 组(2.7±0.1 cm 比 1.4±0.1 cm;p<0.001),但与 SCS 组无显著差异。
目前尚未获得能够明确区分 PASCS 患者与 PA 或 SCS 患者的任何参考标准。但是,当 CT 扫描发现相对较大的肾上腺肿瘤时,临床医生应怀疑 PA 患者同时存在 SCS。